Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 8/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.35 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21722174 | 0.92 | PARP1 (0.39) | SRCNR1H2ALDH1A1MEN1MAPT | |
| SCHEMBL28942832 | 0.81 | NR1H2 (0.49) | NR1H2ALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL1944901 | 0.81 | NR1H2 (0.49) | NR1H2ALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL22805355 | 0.81 | PARP1 (0.35) | NR1H2ALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL22806457 | 0.81 | NR1H2 (0.40) | NR1H2ALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL23555938 | 0.80 | NR1H2 (0.44) | SRCNR1H2ALDH1A1MEN1MAPT | |
| SCHEMBL18655340 | 0.80 | NR1H2 (0.44) | SRCNR1H2ALDH1A1MEN1MAPT | |
| SCHEMBL6730882 | 0.80 | ALDH1A1 (0.40) | NR1H2ALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL25209218 | 0.80 | NR1H2 (0.34) | NR1H2ALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL22805588 | 0.79 | PARP1 (0.34) | NR1H2ALDH1A1MEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7534887-B2 | Thiazoline derivative and use of the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-19 | — | — | US | disclosed |
| US-20070010528-A1 | Thiazoline derivative and use of the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-11 | — | — | US | disclosed |
| EP-1669352-A1 | THIAZOLINE DERIVATIVE AND USE OF THE SAME | Takeda Pharmaceutical Company Limited (JP) | 2006-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010528-A1 | Thiazoline derivative and use of the same | TBXA2R, F2, F3 | SRC 996/4885NR1H2 73/4885ALDH1A1 2163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.